Update on antithrombotic therapy after percutaneous coronary revascularisation

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Percutaneous coronary intervention (PCI) is a standard treatment for coronary obstruction.
• Optimal results from coronary stenting depend on antithrombotic therapy.
• Balancing antithrombotic efficacy and bleeding risk is a long-standing challenge.

Purpose of the Study:

• To review current evidence on antithrombotic therapy after coronary stenting.
• To guide the integration of scientific knowledge into clinical practice.
• To discuss evolving strategies for thrombotic event prevention and bleeding risk reduction.

Main Methods:

• Literature review of current evidence.
• Analysis of drug and device modifications.
• Discussion of clinical decision-making in antithrombotic therapy.

Main Results:

• Significant advancements in drugs and devices have improved patient outcomes.
• The core challenge remains achieving optimal thrombotic protection without increasing bleeding.
• New antiplatelet, anticoagulant agents, and coronary stents offer future solutions.

Conclusions:

• Antithrombotic therapy is crucial for successful percutaneous coronary intervention.
• Continuous innovation in pharmacotherapy and device technology is essential.
• Future research should focus on novel strategies to optimize the benefit-risk ratio.